Givastomig for advanced solid cancers, including gastric and pancreas
Part of Cancer, Digestive system clinical trials.
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is advanced or has spread, and it has either progressed on standard treatment or you have no standard option
- You must have an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 (you can do most daily activities) and have blood/organ tests that look adequate
- You must have a known PD-L1 test result from prior immunohistochemistry testing (and it must have the required CPS score)
- If you’re joining the combination parts (gastric/GEJ/esophagus, pancreas, or biliary tract cancer), your tumor must be CLDN18.2-positive
- You must not have had previous treatments that target CLDN18.2 or 4-1BB (two specific immune-related medicines)
- For the combination parts, you must not have previously received an anti–PD-1 or anti–PD-L1 drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
This trial tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has progressed after immunotherapy. The goal is to see if this combination helps control the cancer longer.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.